Search results
Eli Lilly stock hits all-time high: What’s been driving the pharma giant’s share price higher?
Bankrate via AOL· 5 days agoHowever, investors should remain cautious. The full impact of donanemab on the Alzheimer’s treatment...
Are You Eating Like the Rest of America? How U.S. Diets Have Changed Over 20 Years
SciTechDaily· 6 hours agoAmerican diets show slight improvements over two decades, according to a Tufts University study, yet...
Why Home-Builder Stocks Can Continue Their Bull Run
Barrons.com· 3 days agoHome inventory is up, but still very low and prices remain high. That means builder profits should remain fat. Plus, exploiting the rush to obesity...
Syntis Bio launches oral therapies for metabolic diseases
Pharmaceutical Technology via Yahoo Finance· 6 days agoThe company's lead obesity programme, SYNT-101, is currently undergoing human...other rare disease...
Is Eli Lilly Stock A Buy After FDA Advisors Back Its Alzheimer's Drug?
Investor's Business Daily· 6 days agoMost of the time ARIA is temporary and asymptomatic. But the Food and Drug Administration's advisors...
American diets improve, but remain poor for many, Tufts study says
UPI· 6 hours ago1 of 2 | "What Americans eat is the single biggest driver of our health," said the study's senior...
America’s diet quality moved from an F to a D. Here’s how to turn yours into an A | CNN
CNN.com· 6 hours agoThere’s a crack of light shining through the dark clouds of America’s battle with poor nutrition and...
Eli Lilly doubles investment to $2 billion in Concord pharma facility ahead of opening
Charlotte Observer via Yahoo Finance· 4 days agoAbout Eli Lilly Eli Lilly is known for producing obesity and diabetes drugs, including Jardiance,...
People With Eating Disorders Are Being Prescribed Ozempic — and the Results Are Dire
PopSugar· 6 days agodrug Ozempic, which appears to promise dramatic results for individuals wanting to lose a...
Keros Therapeutics reshuffles leadership team By Investing.com
Investing.com· 7 hours agoKeros Therapeutics, Inc. (NASDAQ:KROS), a biopharmaceutical company engaged in developing treatments...